MedTrace Logo

Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

NCT06740552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1862

Last updated 2026-02-02

No results posted yet for this study

Summary

The goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. The main question it aims to answer is:

Does evolocumab lower risks of major adverse cardiovascular events (MACE) in patients with deferred non-culprit vessel after AMI?

Conditions

  • Multivessel Coronary Artery Disease
  • Acute Myocardial Infarction (AMI)

Interventions

DRUG

Evolocumab

Evolocumab 140mg every two weeks

DRUG

Lipid Lowering Medication

Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.

Sponsors & Collaborators

  • Shanghai Shenkang Hospital Development Center

    collaborator UNKNOWN

  • Tongji Hospital

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • Shanghai 10th People's Hospital

    collaborator OTHER

  • Shanghai General Hospital, China

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2024-12-31
Completion
2025-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06740552 on ClinicalTrials.gov